RBC names specialty pharma and biotech launches to watch in 2025

Ipsen SA

10/12/2024 11:44

** "2025 will be a year of product launches," RBC says in a
note on next year's outlook for European specialty pharma and
biotech companies, as it doesn't expect any major clinical trial
data
    ** Among significant launches in dermatology, RBC names
Almirall's  ALM.MC  and Galderma's  GALD.S  eczema drugs
    ** In the rare disease space, Ipsen  IPN.PA  will launch its
rare liver disease drug Iqirvo, with RBC anticipating sales
around EUR 50 million  ($52.62 million) in 2025
    ** The broker expects Sobi  SOBIV.ST  to replicate Sanofi's
success in Europe with its Altuvoct, which RBC estimates will
bring SEK 1,656 million in sales for 2025
    ** Formycon  FYB.DE  and Sanddoz  SDZ.S  are set to
introduce biosimilar versions of Stelara, a biologic drug, in
the US
    ** The broker's top picks for 2025 are Genmab  GMAB.CO ,
Almirall and Ipsen
    ** It upgrades Hikma  HIK.L  to "outperform" from "sector
perform," citing attractive compounding opportunity

    
    

 (Reporting by Agnieszka Olenska)